Overview

Genetically Risk-Stratified Venetoclax, Ibrutinib, Rituximab (± Navitoclax) in Relapsed/Refractory Mantle Cell Lymphoma

Status:
Not yet recruiting

Trial end date:
2029-06-01

Target enrollment:

Participant gender:

Summary

This is an open label, multi-centre, phase II study in which RR MCL patients will be genetically risk-stratified into Standard risk (no 9p21.1-24.3 loss, no SMARCA2 or SMARCA4 mut/del) and High risk (9p21.1-24.3 loss, SMARCA2 and/or SMARCA4 mut/del). Patients without the high-risk mutations will be treated with ibrutinib, rituximab and venetoclax. Patients with the high-risk mutations will be treated with ibrutinib, rituximab, venetoclax and navitoclax.

Phase:

Phase 2

Details

Lead Sponsor:

Peter MacCallum Cancer Centre, Australia

Treatments:

Navitoclax
Rituximab
Venetoclax